Skip to main content

Catalyst Calendar

Scope
Catalyst

Wed, Sep 30, 2026

1 updates

Fri, Sep 25, 2026

1 updates
MRK
4:30 PM

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

RAHWAY, N.J.–(BUSINESS WIRE)– The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease...

Enrollment • Phase 3merck.com

Thu, Sep 24, 2026

1 updates